Complex Regional Pain Syndrome.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

Conflict of interest statement: Disclosure: Kevin Guthmiller declares no relevant financial relationships with ineligible companies. Disclosure: Anterpreet Dua declares no relevant financial relationships with ineligible companies. Disclosure: Saugat Dey declares no relevant financial relationships with ineligible companies. Disclosure: Matthew Varacallo declares no relevant financial relationships with ineligible companies. 3. Sci Rep. 2025 Jul 16;15(1):25745. doi: 10.1038/s41598-025-11356-5. Evaluation of the efficacy and tolerance of pamidronate in complex regional pain syndrom type 1. Doussiere M(1), Besnier C(2), Hamidou Y(2), Jesson C(2), Danial JS(2), Jarde O(3), Fardellone P(2), Goëb V(2). Author information: (1)Department of Rheumatology, University of Picardie Jules Verne, Amiens-Picardie University Hospital, Amiens, 80054, France. Doussiere.marie@chu-amiens.fr. (2)Department of Rheumatology, University of Picardie Jules Verne, Amiens-Picardie University Hospital, Amiens, 80054, France. (3)Department of Orthopedics, University of Picardie Jules Verne, Amiens-Picardie University Hospital, Amiens, 80054, France. This study aimed to determine whether the delay between symptom onset and treatment initiation, the dose of pamidronate, and bone mineral density (BMD) influence the response to pamidronate treatment in complex regional pain syndrome type 1 (CRPS 1). A retrospective observational study included patients treated with pamidronate between 2013 and 2023. Treatment response was assessed based on symptom regression according to the Budapest criteria at one (M1) and four months (M4) post-treatment. Multivariate logistic regression identified factors associated with response. Among the 255 patients included, 14.5% responded at M1 and 67% at M4. Multivariate analysis showed that post-traumatic (OR 2.75, 95% CI [1.36-5.7], P = 0.0053) or idiopathic etiology (OR 5.47, 95% CI [1.86-18.92], P = 0.0037) compared to post-surgical etiology, and the presence of initial edema (OR 2.39, 95% CI [1.26-4.62], P = 0.0082), were associated with a better response at M4. BMD, treatment delay, and pamidronate dosage were not significantly associated with treatment response. These findings suggest that initial edema is a predictive factor for response to pamidronate in CRPS 1, with syndrome etiology also influencing outcomes. Increasing pamidronate dosage or infusion frequency does not seem to improve therapeutic efficacy. © 2025. The Author(s). DOI: 10.1038/s41598-025-11356-5 PMCID: PMC12267635